Diekmann Fritz, Campistol Josep M
Department of Nephrology and Kidney Transplantation, Hospital Clínic, Villarroel, 170, E-08036 Barcelona, Spain ; Servicio de Nefrología - Clinical Institute of Nephrology and Urology, Hospital Clinic, Barcelona, Spain.
Department of Nephrology and Kidney Transplantation, Hospital Clínic, Villarroel, 170, E-08036 Barcelona, Spain.
Transplant Res. 2015 Dec 22;4(Suppl 1):5. doi: 10.1186/s13737-015-0029-5. eCollection 2015.
Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI.
肾移植后的免疫抑制治疗以钙调神经磷酸酶抑制剂（CNI）为基础。在大多数情况下，CNI治疗与霉酚酸酯和类固醇联合使用。尽管短期效果良好，但这种治疗与长期毒性、移植肾丢失和患者死亡有关。因此，需要替代的免疫抑制策略，将卓越的疗效与低发生率的长期不良后果相结合。本综述重点关注基于mTOR抑制剂并尽量减少CNI暴露的策略。
